About Myriad Genetics, Inc
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. Address: 320 Wakara Way, Salt Lake City, UT, United States, 84108
Myriad Genetics, Inc News and around…
Latest news about Myriad Genetics, Inc (MYGN) common stock and company :
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what ...
Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectivelyEnded the quarter with $339.2 million in cash, cash equivalents and investmentsNew partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selectio
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -4.41% and 12.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:20 p.m. EDT. The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at www.
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to ...
Precise™ Liquid Biopsy will provide insights on circulating tumor DNA in the blood to help guide cancer treatment decisions SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to its growing oncology portfolio. Compared to st
SALT LAKE CITY, April 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on Thursday, May 5, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, R. Bryan Riggsbee, chief financial officer, and Nicole Lambert, chief operating officer, will provide a financial o
Six in 10 of the women surveyed with depression or anxiety diagnosis say they have been ignored or dismissed by family, friends, and/or partners about their mental health concerns Figure 1 Which THREE of the following have helped THE MOST with your DEPRESSION/ANXIETY symptoms to-date? SALT LAKE CITY, April 26, 2022 (GLOBE NEWSWIRE) -- Two out of three women diagnosed with depression or anxiety say they have reached or are approaching their breaking point regarding their mental health, according
The U.S. FDA is warning thatnoninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may ...
Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.
Investors in Myriad Genetics, Inc. (MYGN) saw new options begin trading this week, for the November 18th expiration..
Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.
Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.
Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one easy-to-access solutionSALT LAKE CITY, March 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of Precise™ Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treatment plans for individual patients. The new suite pro
TheFDA has approvedAstraZeneca Plc's(NASDAQ: AZN) cancer drug, jointly developed withMerck & Co ...
BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancerSALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the U.S. Food and Drug Administration (FDA) has approved Myriad’s BRACAnalysis® CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) HER2 ne
Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage SALT LAKE CITY, March 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has been recognized on Fast Company’s annual list of the World’s Most Innovative Companies for 2022. The list honors businesses that are making the biggest impact in their industries, providing a roadmap for the f
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.
SALT LAKE CITY, March 02, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 8, 2022 at 9:50 a.m. ET. Diaz will share insights on the growing role of genetic insights in context with industry trends, new commercial capabilities and products that advance health equity and enable healthcare providers to
Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders are probably feeling a little disappointed, since its shares fell...
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.
Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Highlights: Strong business performance despite COVID-19 headwindsRevenue of $160.8 million in the fourth quarter and $690.6 million for the year ended Dec. 31, 2021, up 4% and 24%, respectively Excluding revenue from divested businesses, revenue increased 19% for the fourth quarter and 34% for the year Diluted GAAP earnings per share (EPS) of $(0.10) and adjusted EPS of $(0.02) in the fourth quarter of 2021Ended the quarter with $398.8 million in cash, cash equivalents and investments SALT LAKE
Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorderSALT LAKE CITY, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis of GeneSight® Psychotropic, the company’s mental health medication test, in its Feb. 2022 edition. The study sh
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.
Myriad Genetics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
MYGN earnings call for the period ending September 30, 2021.
Myriad Genetics, Inc (MYGN) is a NASDAQ Common Stock listed in Common Stock, Diagnostics & Research, Healthcare
